Identification of Prognostic Biomarkers and Drugs Targeting Them in Colon Adenocarcinoma: A Bioinformatic Analysis

Shu Dong, MD, Zhimin Ding, MD, Hao Zhang, MD, and Qiwen Chen, MD

Abstract

Objective: To identify prognostic biomarkers and drugs that target them in colon adenocarcinoma (COAD) based on the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus databases. Methods: The TCGA dataset was used to identify the top 50 upregulated differentially expressed genes (DEGs), and Gene Expression Omnibus profiles were used for validation. Survival analyses were conducted with the TCGA dataset using the RTCGA toolbox package in the R software environment. Drugs targeting the candidate prognostic biomarkers were searched in the DrugBank and herbal databases. Results: Among the top 50 upregulated DEGs in patients with COAD in the TCGA dataset, the Wnt signaling pathway and cytokine-cytokine receptor interactions and pathways in cancer Kyoto Encyclopedia of Genes and Genomes pathway analysis were enriched in DEGs. Tissue development and regulation of cell proliferation were the main Gene Ontology biological processes associated with upregulated DEGs. MYC and KLK6 were overexpressed in tumors validated in the TCGA, GSE41328, and GSE113513 databases (all \( p < .001 \)) and were significantly associated with overall survival in patients with COAD (\( p = .021 \) and \( p = .047 \)). Nadroparin and benzamidine were identified as inhibitors of MYC and KLK6 in DrugBank, and 8 herbs targeting MYC, including Da Huang (Radix Rhei Et Rhizome), Hu Zhang (Polygoni Cuspidati Rhizoma Et Radix), Huang Lian (Coptidis Rhizoma), Ban Xia (Arun Ternatum Thunb), Tu Fu Ling (Smilacis Glabrae Rhixoma), Lei Gong Teng (Tripterygii Radix), Er Cha (Catechu), and Guang Zao (Choerospondiatis Fructus), were identified. Conclusion: MYC and KLK6 may serve as candidate prognostic predictors and therapeutic targets in patients with COAD.

Keywords
colon adenocarcinoma, colorectal carcinoma, MYC, kallikrein-related peptidase, KLK6

Submitted January 25, 2019; revised June 6, 2019; accepted June 14, 2019

Introduction

Over the past few decades, colorectal cancer (CRC) incidence and mortality has steadily declined worldwide; however, CRC is still the most common gastrointestinal malignancy and the second leading cause of cancer-related death.1 At present, the only curative treatment for CRC is surgical resection, and only modest survival has been reported with chemotherapy.2 The use of chemotherapy and surgical resection for the treatment of malignant colon cancer is increasing, but the results of these treatments have not considerably improved. Approximately half of CRCs recur, and the patients die within 5 years.2,3 Biomarkers can be used as prognostic indicators, molecular predictive factors, and determiners of targeted therapy.4,5

1Fudan University Shanghai Cancer Center, Shanghai, China
2Shanghai Medical College, Fudan University, Shanghai, China
3Shanghai Proton and Heavy Ion Center, Shanghai, China
4Fudan University, Shanghai, China
*Shu Dong and Zhimin Ding contributed equally to this work.

Corresponding Authors:
Qiwen Chen, Department of Integrative Oncology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai 200032, China.
Email: cqwly@hotmail.com
Hao Zhang, Department of Pathology, Fudan University Shanghai Cancer Center, 270 Dong-An Road, Shanghai 200032, China.
Email: 18917740070@163.com
Colon adenocarcinoma (COAD) has been understood to result from genetic and epigenetic alterations that initiate cancer development and help the progression of cancer. Oncogenes, which serve as tumor therapeutic targets, promote cancer cell growth and metastasis and have been widely evaluated. Many prognostic markers have been evaluated in COAD; however, most are experimental or have not been prospectively validated. This study aimed to identify upregulated differentially expressed genes (DEGs) in COAD tumors and nontumor tissues, identify enriched functional pathways, analyze survival outcomes, and search for potential drugs that target the identified DEGs in hope of finding novel and reliable prognostic biomarkers in COAD development.

Materials and Methods

Source of Data

The COAD TGCA (The Cancer Genome Atlas) dataset, updated January 28, 2016, was downloaded (https://cancergenome.nih.gov/). Clinical data and gene expression data including mRNA array and RNA seq data were downloaded using the RTCGAToolbox package in the R software environment. Gene Expression Omnibus (https://www.ncbi.nlm.nih.gov/geo/) databases GSE41328 and GSE113513 were used for validation of the DEGs identified in the TCGA dataset. Tumor samples and microarray processing data were available for these 2 profiles in the Gene Expression Omnibus database. In total, 10 and 14 pairs of COAD samples were included in GSE41328 and GSE113513, respectively.

Functional Enrichment

The inclusion criteria for identification of upregulated DEGs were set as logFC > 2 and adjusted \( P < .05 \). The top 50 upregulated DEGs were selected for heat map and functional enrichment. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) biological process enrichment analysis of upregulated DEGs was conducted using Gene Set Enrichment Analysis (GSEA; http://software.broadinstitute.org/gsea/index.jsp). To investigate the enrichment of gene sets, upregulated DEGs were uploaded to the Molecular Signatures Database in GSEA. A false discovery rate \( P \) value cutoff of <.05 was set as the screening condition. The top 10 KEGG pathways and GO biological processes were presented.

Survival Analysis

Kaplan-Meier survival analysis for upregulated DEGs was conducted in the R software environment using the RTCGAToolbox package and the getSurvival function. All the upregulated DEGs were grouped using median cut-off values into high expression or low expression groups. The R programming script for the survival analysis is attached in the Supplementary Materials.

Analysis of Associated Diseases

After candidate prognostic biomarkers for COAD were detected, the highest scored disease associations for the candidates were identified in the DisGeNET database (http://www.disgenet.org/web/DisGeNET/menu/home).

Analysis of Targeting Drugs

The DrugBank database (https://www.drugbank.ca/) was used to identify drugs targeting the candidate biomarkers. The Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP; http://lsp.nwu.edu.cn/tcmsp.php) and the TCM-MESH (http://mesh.tcm.microbioinformatics.org/) databases were used to identify herbs targeting the candidate biomarkers.

Results

Top 50 DEGs in COAD

Using the RTCGAToolbox package in the R software environment, mRNA array gene expression data in tumor and nontumor tissues of patients with COAD in the TCGA dataset were downloaded and analyzed to identify upregulated DEGs. As shown in Figure 1, the top 50 upregulated DEGs between tumor and nontumor samples were identified.

Functional Enrichment of DEGs

Using the GSEA online service, the enrichment of KEGG pathways and GO biological processes in upregulated DEGs was analyzed. As shown in Figure 2, the Wnt signaling pathway, cytokine-cytokine receptor interaction, and pathways in cancer KEGG pathways were enriched in more of the top 50 upregulated DEGs. Tissue development, regulation of cell proliferation, and regulation of multicellular organismal development were the main GO biological processes among the top 50 upregulated DEGs.

Survival Analysis and Expression Comparison

Using the getSurvival function of RTCGAToolbox package in the R software environment, Kaplan-Meier survival analysis was performed. Among the top 50 upregulated DEGs, COAD patients with MYC overexpression in tumor tissues had significantly worse overall survival (OS) than those with low MYC expression (\( P = .021 \); Figure 3A). And, high KLK6 was significantly associated with poor OS in COAD patients (\( P = .047 \); Figure 3B).

As shown in Figure 4, MYC and KLK6 were overexpressed in tumor tissues compared with nontumor tissues
In GSE41328 and GSE113513 validation sets, MYC was upregulated in tumor tissues (both \( P < .0001 \); Figure 4A). Similarly, KLK6 was also significantly overexpressed in tumor tissues in both GSE41328 and GSE113513 validation sets (\( P = .0068 \) and \( P < .0001 \), respectively; Figure 4B and C).

**Associated Diseases and Drugs Targeting MYC and KLK6**

Using the DisGeNET online service, MYC and KLK6 were both included in the top-scored disease associations of colonic neoplasms and colorectal neoplasms (Figure 5). In the DrugBank database, when MYC and KLK6 were set as drug targets, nadroparin and benzamidine were identified, respectively. Nadroparin is an approved and investigational MYC inhibitor, and the use of benzamidine for KLK6 is still in experimental stages.

In the TCMSP database, 259 herbs were related to MYC, and no herbs were related to KLK6. In the TCM-MESH database, 61 herbs related to MYC and 15 herbs related to KLK6 were identified. Between the 2 databases, 8 herbs targeting MYC were found in common, including *Da Huang* (*Radix Rhei Et Rhizome*), *Hu Zhang* (*Polygoni Cuspidati Rhizoma Et Radix*), *Huang Lian* (*Coptidis Rhizoma*), *Ban Xia* (*Arum Ternatum Thunb*), *Tu Fu Ling* (*Smilacis Glabrae Rhizoma*), *Lei Gong Teng* (*Tripterygii Radix*), *Er Cha* (*Catechu*), and *Guang Zao* (*Choerospondiatis Fructus*) (Figure 6).

Functionally, *Da Huang*, *Hu Zhang*, and *Huang Lian* have heat-clearing and detoxifying effects, *Ban Xia* has phlegm-resolving and damp-drying effects, *Tu Fu Ling* and *Lei Gong Teng* have collateral-unblocking and toxin-relieving effects, and *Er Cha* and *Guang Zao* have blood-activating effects (Figure 6). Thus, eliminating pathogenic factors rather than strengthening the body’s resistance might be more effective for cancer treatment targeting MYC.
Figure 2. GO biological process and KEGG pathway enrichment of the top 50 upregulated DEGs from the TCGA colorectal carcinoma dataset.

Figure 3. Overall survival of patients with colorectal carcinoma grouped by MYC (A) and KLK6 (B) with median cutoff.
Discussion

Previous studies have revealed that overexpression of MYC, which is triggered by activation of the Wnt pathway, is considered to be a marker of metastasis and a prognostic factor for good survival. As a regulator of cell proliferation and apoptosis, elevated expression of MYC mRNA and increased expression of MYC oncoprotein were reported in the majority of CRCs, induced epithelial-mesenchymal

Figure 4. MYC and KLK6 levels in nontumor and tumor tissues in the TCGA dataset (A), GSE41328 GEO profile (B), and GSE113513 GEO profile (C).
transition, and significantly correlated with advanced tumor stage. Furthermore, primary tumors were significantly more diffusely positive for MYC than metastatic tumors. A previous report showed that MYC on its own failed to have independent prognostic significance but coexpression of nuclear β-catenin and MYC was the strongest marker of...
impaired prognosis.26 Our results showed that MYC overexpression in tumors was significantly associated with COAD survival. Hence, the inhibition of MYC is a promising therapeutic strategy for treating COAD.27 In this analysis, we identified potential drugs targeting MYC, such as nadroparin, and 8 herbs with pathogenic factor–eliminating effects that also target MYC. Nadroparin has both protective and therapeutic effects against colonic inflammation via exerting anti-oxidative and anti-inflammatory effects by modulating nuclear factor E2-related factor-2/heme oxygenase-1 (Nrf2/HO-1) and nuclear factor kappa B (NF-κB) pathways.28 This might also be the antitumor mechanism of nadroparin in COAD.

It has been reported that emodin, a phytochemical of Da Huang and Hu Zhang, can inhibit the proliferation of the HT-29 human colon cancer cell line in vitro in a dose-dependent and time-dependent manner.29 Moreover, emodin inhibits colon cancer cell proliferation, migration and metastasis via activating caspase-3, downregulating of CCR4 and Foxp3, and suppressing STAT3 and the AKT/mTOR signaling pathway.30,31 In addition, the Hu Zhang phytochemical resveratrol can inhibit the proliferation of HCT-15 cells and induce cell apoptosis by arresting the cells in S phase.32 Berberine (a phytochemical of Huang Lian) can significantly inhibit the proliferation of Caco-2 cells by inducing cell cycle arrest and cell apoptosis.33 Total alkaloids extracted from Huang Lian can inhibit tumor formation induced by 1-2 dimethylhydrazine (DMH) combined with dextran sodium sulfate solution (DSS).34 Banxia Xie Xin Decotion was found to suppress colon carcinogenesis induced by DMH/DSS by stopping colitis from developing into colonic carcinoma.35 Celastrol, a phytochemical from Lei Gong Teng, inhibited proliferation of SW620 cells by downregulating p-AKT, NF-xB, and survivin, and activating caspase-7, caspase-3, and PARP. Additionally, celastrol induced the expression of reactive oxygen species, apoptosis, depolarization of the mitochondrial membrane, and cell cycle arrest at G2/M in SW620 cells.36 Triptolide can induce apoptosis of HCT16 cells by inhibiting Bcl-2, increasing Bax, and promoting the activation of caspase-337; it can also induce autophagy in CT26 colon cancer cells.38 No publications on the antitumor effects of Tu Fu Ling, Er Cha, and Guang Zao on colon cancer were found. We suggest more research on these herbs, both in compounds and as ingredients for COAD treatments.

Aberrant expression of KLK6 was reported in several human cancers, including breast,39 pancreatic,40 gastric,41 and colon cancer.42 High expression of KLK6 mRNA correlated with serosal invasion, liver metastasis, advanced Duke’s stage, and a poor prognosis for patients with CRC.42 KLK6 mRNA was significantly upregulated in highly invasive tumors and tumors with advanced TNM stage and was shown to predict poor OS and disease-free survival in CRC.43 Another study by Vakrakou et al also proved that KLK6 expression correlates significantly with increasing tumor stage and histological grade and is a significant factor for OS and disease-free survival in COAD.44 Interestingly, KLK6 levels in adenomas were significantly higher than those in either the cancerous or non-cancerous tissues examined. Strong KLK6 immunostaining was seen in glandular cells and inflammatory cells of adenomas.44,45 Our results confirmed the predictive value of KLK6 for COAD outcomes in agreement with previous publications. As an inhibitor of KLK6, benzamidine showed antitumor activity in human promyelocytic leukemia cells46 and B-lymphoid human tumor cells.47 However, the use of benzamidine to target KLK6 is still in experimental stages, and no herbs and ingredients were identified as related to KLK6 in COAD.

Even though MYC was a promising anticancer target of traditional Chinese medicine including Ban Xia, Da Huang, and Lei Gong Teng in many human malignancies,48-50 no evidence of these drugs and herbs acting on CRC including COAD through targeting of MYC an KLK6 was identified. Our results indicated that MYC and KLK6, which are overexpressed in tumor tissues, may represent potential molecular biomarkers for unfavorable prognosis in COAD. Understanding the biological function and mechanisms of MYC and KLK6 in colorectal tissue may help delineate their roles in colorectal physiology and the pathology of CRCs. Unfortunately, MYC and KLK6 were examined at the transcription level, not at the protein level. Additionally, no experimental mechanisms of these genes were investigated. We suggest that future basic research and clinical studies should focus on the associations between these genes and COAD development and progression.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by National Natural Science Foundation of China (81503524/H2708) and Foundation from Shanghai Science and Technology Committee (14401932400).

ORCID iD
Shu Dong https://orcid.org/0000-0002-7293-9557

Supplemental Material
Supplemental material for this article is available online.

References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7-30.
2. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490-1502.
3. Effendi-Ys R. Cancer stem cells and molecular biology test in colorectal cancer: therapeutic implications. *Acta Med Indones.* 2017;49:351-359.

4. Mody K, Bekasi-Saab T. Clinical trials and progress in metastatic colon cancer. *Surg Oncol Clin N Am.* 2018;27:349-365.

5. Garcia-Alfonso P, Garcia-Foncillas J, Salazar R, et al. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. *Clin Transl Oncol.* 2015;17:264-273.

6. Puerta-Garcia E, Cañadas-Garre M, Calleja-Hernández MA. Molecular biomarkers in colorectal carcinoma. *Pharmacogenomics.* 2015;16:1189-1222.

7. Harrison S, Benziger H. The molecular biology of colorectal carcinoma and its implications: a review. *Surgery.* 2011;9:200-210.

8. Oliveira DM, Grillone K, Mignogna C, et al. Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: identification of gain-of-function mutations in the RET proto-oncogene. *J Exp Clin Cancer Res.* 2018;37:84.

9. Yang Q, Hou C, Huang D, et al. miR-455-5p functions as a potential oncogene by targeting galectin-9 in colon cancer. *Oncol Lett.* 2017;13:1958-1964.

10. Samur MK. RTCGAToolbox: a new tool for exporting TCGA Firehose data. *PLoS One.* 2014;9:e106397.

11. Mootha VK, Lindgren CM, Eriksson KF, et al. PGC-1alpha-coordinated downregulated in human diabetes. *PLoS One.* 2009;3:e106397.

12. Subramanian A, Tamayo P, Mootha VK, et al. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. *Clin Transl Oncol.* 2015;17:264-273.

13. Piñero J, Bravo À, Queralt-Rosinach N, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Res.* 2017;45(D1):D833-D839.

14. Pinero J, Queralt-Rosinach N, Bravo À, et al. DisGeNET: a discovery platform for the dynamical exploration of human diseases and their genes. *Database (Oxford).* 2015;2015:bav028.

15. Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. *Nucleic Acids Res.* 2018;46(D1):D1074-D1082.

16. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledge-base for drugs, drug actions and drug targets. *Nucleic Acids Res.* 2008;36(database issue):D901-D906.

17. Ru J, Li P, Wang J, et al. TCMSPI: a database of systems pharmacology for drug discovery from herbal medicines. *J Cheminform.* 2014;6:13.

18. Zhang RZ, Yu SJ, Bai H, Ning K. TCM-Mesh: the database and analytical system for network pharmacology analysis for TCM preparations. *Sci Rep.* 2017;7:2821.

19. Rennoll S, Yochum G. Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer. *World J Biol Chem.* 2015;6:290-300.

20. Toon CW, Chou A, Clarkson A, et al. Immunohistochemistry for MYC predicts survival in colorectal cancer. *PLoS One.* 2014;9:e87456.

21. He X, Tan X, Wang X, et al. C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion. *Tumour Biol.* 2014;35:12181-12188.

22. Li N, Wang J, Shen S, Bu X, Tian X, Huang P. Expression of p53, Ki-67, and c-Myc proteins is predictive of the surgical molecular margin in colorectal carcinoma. *Pathol Oncol Res.* 2011;17:479-487.

23. Zalata KR, Elshaf MF, Foda AA, Shoma A. Genetic dissimilarity between primary colorectal carcinomas and their lymph node metastases: ploidy, p53, bel-2, and c-myc expression—a pilot study. *Tumour Biol.* 2015;36:6579-6584.

24. Zhu W, Cai MY, Tong ZT, et al. Overexpression of EIF5A2 promotes colorectal carcinoma cell aggressiveness by upregulating MTA1 through C-myc to induce epithelial-mesenchymal transition. *Gut.* 2012;61:562-575.

25. Liu Y, Yang Y, Xu H, Dong X. Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a, p14ARF, and cyclin D2 expression in primary colorectal carcinomas. *Diagn Mol Pathol.* 2010;19:194-200.

26. Bondi J, Bukholm G, Nesland JM, Bukholm IR. Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. *APMIS.* 2004;112:49-56.

27. Li W, Zhu W, Lv C, et al. Low-dose paclitaxel downregulates MYC proto-oncogene bHLH transcription factor expression in colorectal carcinoma cells. *Oncol Lett.* 2018;15:1881-1887.

28. Yalniz M, Demirel U, Orban C, et al. Nadorarinodium activates Nr2/HO-1 pathway in acetic acid-induced colitis in rats. *Inflammation.* 2012;35:1213-1221.

29. Cao YY, Zuo WY, Zhang J, Cao J. Inhibitory action of emodin on proliferation of colon cancer cell HT-29 in vitro. *Shanghai J Tradit Chin Med.* 2012;46(9):81-84.

30. Ruan ZY, Deng XL, Wang LH, et al. The inhibiting effects of emodin on mice colon cancer CT26. WT cells in vitro. *Guangdong Med J.* 2013;34:1797-1800.

31. Wang MJ, Wang YY, Fan JB. Emodin’s suppression on metastasis of colorectal cancer. *J Chengdu Med Coll.* 2016;11(1):16-20.

32. Hu M, Song YQ. Effect of resveratrol on the cell proliferation and apoptosis of human colon cancer HCT-15 cells. *Zhijiang J Integrated Tradit Chin West Med.* 2017;27:1032-1034.

33. Wang JH, Bao YR, Meng XS, Wang S, Li TJ. Effects of berberine on apoptosis and cell cycle of human colorectal cancer cell line Caco-2. *Central South Pharmacy.* 2018;16(1):64-67.

34. Wu K, He BC, Zhou QX. Chemopreventive effect of total alkaloids from corptidis rhizoma on experimental colon cancer in rats. *Chin J Exp Tradit Med Formulae.* 2016;11(1):16-20.

35. Hu M, Song YQ. Effect of resveratrol on the cell proliferation and apoptosis of human colon cancer HCT-15 cells. *Zhijiang J Integrated Tradit Chin West Med.* 2017;27:1032-1034.

36. Wang JH, Bao YR, Meng XS, Wang S, Li TJ. Effects of berberine on apoptosis and cell cycle of human colorectal cancer cell line Caco-2. *Central South Pharmacy.* 2018;16(1):64-67.

37. Wu K, He BC, Zhou QX. Chemopreventive effect of total alkaloids from corptidis rhizoma on experimental colon cancer in rats. *Chin J Exp Tradit Med Formulae.* 2016;11(1):16-20.
38. Zhang TJ, Han S, Zhang W, Zhao FJ, Li J. Triptolide promoting colon cancer CT26 cell death through induction of autophagy. *Acta Anat Sin (Chin)*. 2016;47:774-778.

39. Sidiropoulos KG, Ding Q, Pampalakis G, et al. KLK6-regulated miRNA networks activate oncogenic pathways in breast cancer subtypes. *Mol Oncol*. 2016;10:993-1007.

40. Rückert F, Hennig M, Petraki CD, et al. Co-expression of KLK6 and KLK10 as prognostic factors for survival in pancreatic ductal adenocarcinoma. *Br J Cancer*. 2008;99:1484-1492.

41. Kim JJ, Kim JT, Yoon HR, et al. Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer. *Tumour Biol*. 2012;33:731-738.

42. Ogawa K, Utsunomiya T, Mimori K, et al. Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. *Clin Cancer Res*. 2005;11:2889-2893.

43. Christodoulou S, Alexopoulou DK, Kontos CK, Scorilas A, Papadopoulos IN. Kallikrein-related peptidase-6 (KLK6) mRNA expression is an independent prognostic tissue biomarker of poor disease-free and overall survival in colorectal adenocarcinoma. *Tumour Biol*. 2014;35:4673-4685.

44. Vakrakou A, Devetzi M, Papachristopoulou G, et al. Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma. *Biol Chem*. 2014;395:1105-1117.

45. Kim JT, Song EY, Chung KS, et al. Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer. *Cancer*. 2011;117:2608-2619.

46. Saiko P, Osvvar-Kozma M, Bernhaus A, et al. N-hydroxy-N'-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: synergistic antitumor activity with arabinofuranosyletosine. *Int J Oncol*. 2007;31:1261-1266.

47. Nastuzzi C, Feriott G, Barbieri R, Ferroni R, Guarneri M, Gambari R. Differential effects of benzamidine derivatives on the expression of c-myc and HLA-DR alpha genes in a human B-lymphoid tumor cell line. *Cancer Lett*. 1988;38:297-305.

48. Huang J, Zhang WY. Effects of the ethanolic extract from *Pinellia ternata* on cell proliferation and cell cycle of human hepatoma HepG2 cell line. *J China Pharm Univ*. 2009;40(1):89-93.

49. Huang LY, Hu JD, Chen XJ, Zhu LF, Hu HL. Effects of emodin on the proliferation inhibition and apoptosis induction in HL-60 cells and the involvement of c-myc gene [in Chinese]. *Zhonghua Xue Ye Xue Za Zhi*. 2005;26:348-351.

50. Chen JY, Gu QL, Kuai YH, Ou YT, Wang LJ, Li WD. Suppression of triptolide on the proliferation of human breast cancer cells. *J Guangdong Pharm Univ*. 2016;32:352-354.